Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Ampol Profit Surges as Refining Margins Hit Record Highs 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Add as a preferred source on Google
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
